Cerapedics, a Westminster, CO-based orthobiologics company, raised a total of $8m.
This includes a $4m in equity financing from internal investors and a $4m term loan from GE Capital, Healthcare Financial Services.
The company intends to use the funds to advance the development of i-FACTOR™ biologic bone graft for which it filed a Premarket Approval Application (PMA) with the U.S. Food & Drug Administration in September 2014, and to expand commercialization in markets outside the U.S.
Led by Glen Kashuba, CEO, Cerapedics focuses on developing and commercializing its proprietary synthetic small peptide (P-15) technology platform. The i-FACTOR™ biologic bone graft incorporates a small peptide as an attachment factor to stimulate the natural bone healing process.
18/04/2014: Cerapedics Closes $9M Venture Debt Financing from GE Capital
12/12/2012: Cerapedics Completes $19M Series C Financing